MorphoSys saw the highest growth of 139% in patent filings in January and 249% in grants in March in Q1 2024. Compared to Q4 2023, Q1 2024 saw an increase in patent filings by 139% and grants by 99%. GlobalData’s DataBook provides a comprehensive analysis of MorphoSys‘s patent filings and grants. Buy the databook here.
MorphoSys has been focused on protecting inventions in Israel(IL) with seven publications in Q1 2024
The Israel(IL) Patent Office dominates the patent filings and grants with nearly 8% filings and 22% grants. The China(CN), European Patent Office(EPO), Australia(AU), and United States(US) patent Office are among the top ten patent offices where MorphoSys is filings its patents. Among the top granted patent authorities, MorphoSys has 22% of its grants in Israel(IL), 11% in European Patent Office(EPO) and 11% in Australia(AU).
F. Hoffmann-La Roche and Bristol-Myers Squibb could be the strongest competitors for MorphoSys
Patents related to rare diseases lead MorphoSys's portfolio
MorphoSys has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q1 2024.
Chronic lymphocytic leukemia (cll) related patents lead MorphoSys portfolio followed by hodgkin lymphoma (b-cell hodgkin lymphoma), and lymphoma
MorphoSys has highest number of patents in chronic lymphocytic leukemia (cll) followed by hodgkin lymphoma (b-cell hodgkin lymphoma), lymphoma, multiple myeloma (kahler disease), and acute lymphocytic leukemia (all, acute lymphoblastic leukemia). For chronic lymphocytic leukemia (cll), nearly 3% of patents were filed and 13% of patents were granted in Q1 2024.
For comprehensive analysis of MorphoSys's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.